Alcon Inc (ALC)
80.35
-0.62
(-0.77%)
USD |
NYSE |
May 08, 16:00
80.36
0.00 (0.00%)
Pre-Market: 20:00
Alcon Enterprise Value: 43.26B for May 8, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 08, 2024 | 43.26B |
| May 07, 2024 | 43.57B |
| May 06, 2024 | 43.29B |
| May 03, 2024 | 42.88B |
| May 02, 2024 | 42.31B |
| May 01, 2024 | 42.36B |
| April 30, 2024 | 41.89B |
| April 29, 2024 | 42.46B |
| April 26, 2024 | 42.48B |
| April 25, 2024 | 42.52B |
| April 24, 2024 | 42.88B |
| April 23, 2024 | 43.46B |
| April 22, 2024 | 43.39B |
| April 19, 2024 | 42.87B |
| April 18, 2024 | 42.33B |
| April 17, 2024 | 42.59B |
| April 16, 2024 | 42.90B |
| April 15, 2024 | 43.63B |
| April 12, 2024 | 43.72B |
| April 11, 2024 | 44.23B |
| April 10, 2024 | 44.17B |
| April 09, 2024 | 44.41B |
| April 08, 2024 | 44.98B |
| April 05, 2024 | 45.46B |
| April 04, 2024 | 44.87B |
| Date | Value |
|---|---|
| April 03, 2024 | 45.10B |
| April 02, 2024 | 43.93B |
| April 01, 2024 | 44.08B |
| March 28, 2024 | 44.71B |
| March 27, 2024 | 44.71B |
| March 26, 2024 | 44.38B |
| March 25, 2024 | 44.55B |
| March 22, 2024 | 44.87B |
| March 21, 2024 | 45.02B |
| March 20, 2024 | 45.36B |
| March 19, 2024 | 45.42B |
| March 18, 2024 | 45.12B |
| March 15, 2024 | 45.54B |
| March 14, 2024 | 46.01B |
| March 13, 2024 | 46.70B |
| March 12, 2024 | 47.10B |
| March 11, 2024 | 47.11B |
| March 08, 2024 | 46.68B |
| March 07, 2024 | 46.50B |
| March 06, 2024 | 45.92B |
| March 05, 2024 | 45.55B |
| March 04, 2024 | 46.00B |
| March 01, 2024 | 46.41B |
| February 29, 2024 | 45.33B |
| February 28, 2024 | 45.89B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
22.07B
Minimum
Mar 23 2020
47.11B
Maximum
Mar 11 2024
36.64B
Average
37.24B
Median
Jun 22 2021
Enterprise Value Benchmarks
| AC Immune SA | 109.73M |
| CRISPR Therapeutics AG | 2.830B |
| Addex Therapeutics Ltd | 5.016M |
| NLS Pharmaceutics Ltd | -- |
| Molecular Partners AG | -98.97M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 427.00M |
| Revenue (Quarterly) | 2.352B |
| Total Expenses (Quarterly) | 2.144B |
| EPS Diluted (Quarterly) | 0.86 |
| Gross Profit Margin (Quarterly) | 54.85% |
| Profit Margin (Quarterly) | 18.15% |
| Earnings Yield | 2.44% |
| Operating Earnings Yield | 2.61% |
| Normalized Earnings Yield | 2.439 |